Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statement of Cash Flows Data:
Net loss	$ (8,052,102)us-gaap_NetIncomeLoss	$ (10,782,168)us-gaap_NetIncomeLoss
Gain on revaluation of derivative warrants	(2,285,157)	(2,373,941)
Scenario, Previously Reported [Member]
Consolidated Statement of Cash Flows Data:
Net loss	(8,106,395)
Gain on revaluation of derivative warrants	(2,230,864)
Restatement Adjustment [Member]
Consolidated Statement of Cash Flows Data:
Net loss	54,293
Gain on revaluation of derivative warrants	$ (54,293)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.